AIM ImmunoTech Inc.
AIM ImmunoTech Inc. (AIM): 33 pipeline candidates · 23 upcoming catalysts · ~7 mo cash runway · 9 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
6.6 months
D/E 3.04 · 0% dilution
Lead: Approved
33 candidates
23 upcoming, next in ~36d
N/A
A transparent, data-derived signal for AIM ImmunoTech Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$11.2M
Cash
$5.8M
Quarterly Burn
$2.7M
Runway
6.6 mo
Revenue
$22K
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (33 candidates)
| Drug | Phase |
|---|---|
| alferon n | Approved |
| Alpha-type-1 Polarized Dendritic Cells | Phase 2 |
| ampligen | Phase 2 |
| Ampligen (rintatolimod) | Phase 2 |
| Buprenorphine | Phase 4 |
| Celecoxib | Phase 2 |
| Control | Phase 4 |
| Cytarabine | Phase 2 |
| Cytarabine IT | Phase 2 |
| Enhanced Recovery After Surgery | Phase 4 |
Showing 10 of 33 candidates. Sign up for full pipeline.
Upcoming Catalysts (23)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
14
Total value held
$52K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 29,918 | $18K |
| xtx topco ltd | 20,590 | $12K |
| jane street group, llc | 20,047 | $12K |
| vanguard fiduciary trust co | 17,519 | $10K |
| morgan stanley | 864 | $505 |
| harbour investments, inc. | 32 | $19 |
| creative financial designs inc /adv | 30 | $18 |
| hrt financial lp | 26,032 | $15 |
| osaic holdings, inc. | 15 | $7 |
| hoey investments, inc | 10 | $6 |
Showing top 10 of 14 institutional holders of AIM ImmunoTech Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in AIM ImmunoTech Inc.'s pipeline?
AIM ImmunoTech Inc. (AIM) has 33 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is AIM ImmunoTech Inc.'s lead drug candidate?
AIM ImmunoTech Inc.'s most advanced tracked candidate is alferon n (Approved) for refractory or recurring external genital warts.
What is AIM ImmunoTech Inc.'s next catalyst?
AIM ImmunoTech Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: AKTEN" — expected July 24, 2026.
What is AIM ImmunoTech Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, AIM ImmunoTech Inc. has approximately 6.6 months of cash runway.
What is AIM ImmunoTech Inc.'s market capitalization?
AIM ImmunoTech Inc.'s market capitalization is approximately $11.2M.
Get the full picture on AIM ImmunoTech Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.